SCHEDULE: Perceptive Advisors Discloses 9.99% Stake in enGene Holdings
Beneficial Ownership Disclosure
Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., reported a 9.99% beneficial ownership stake in enGene Holdings Inc. common shares.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have disclosed a beneficial ownership of 6,770,605 common shares of enGene Holdings Inc.
- This represents 9.99% of the company's outstanding common shares.
- The ownership percentage is based on 64,578,185 outstanding shares reported by enGene Holdings Inc. in a November 14, 2025 prospectus supplement, plus 2,294,117 additional shares from an underwriters' over-allotment option.
- Perceptive Life Sciences Master Fund, Ltd. directly holds 5,869,076 common shares and 2,735,295 pre-funded warrants.
- Due to a beneficial ownership limitation, only 901,529 of the pre-funded warrants are currently exercisable, preventing the Reporting Persons from exceeding 9.99% ownership.
- Perceptive Advisors serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors.
Sentiment
Score: 7
Explanation: The disclosure of a significant stake by a reputable institutional investor like Perceptive Advisors is generally viewed positively, indicating confidence in the company's future. The 9.99% ownership limit on warrants is a minor constraint for the investor but doesn't detract significantly from the overall positive signal.
Positives
- Significant institutional investment from Perceptive Advisors, a well-known life sciences investor, signals confidence in enGene Holdings Inc.
- The 9.99% stake is a substantial position, indicating a strong conviction in the company's prospects.
Negatives
- The beneficial ownership limitation of 9.99% restricts the Reporting Persons from exercising all their pre-funded warrants, potentially limiting their upside from these instruments.
Risks
- The beneficial ownership limitation on pre-funded warrants means the Reporting Persons cannot increase their stake beyond 9.99% through warrant exercise, which could be a constraint on their investment strategy.
Future Outlook
The filing does not contain specific forward-looking statements or guidance from enGene Holdings Inc. regarding its future performance or operations.
Industry Context
This filing indicates a significant investment by a specialized life sciences fund, Perceptive Advisors, into enGene Holdings Inc., a common occurrence in the biotechnology and pharmaceutical sectors where institutional investors often take substantial positions in promising early to mid-stage companies. Such investments can provide capital and validate a company's potential.
Stakeholder Impact
- Shareholders: May view the significant institutional investment as a positive signal, potentially increasing confidence and attracting further investment.
- Company Management: Benefits from the validation and potential long-term support of a major institutional investor.
Key Dates
| Date | Description |
|---|---|
| 2025-11-11 | Date of event requiring the filing of this statement (acquisition of beneficial ownership exceeding 5%). |
| 2025-11-14 | Date of prospectus supplement filing by enGene Holdings Inc. reporting outstanding shares. |
| 2025-11-18 | Date of signing of the Schedule 13G filing. |
Keywords
enGene Holdings Inc., Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Schedule 13G, beneficial ownership, institutional investment, common shares, pre-funded warrants, biotechnology, healthcare investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.